Leukocytosis and Tobacco Use : An Observational Study of Asymptomatic Leukocytosis
Copyright © 2020 Elsevier Inc. All rights reserved..
PURPOSE: This study aimed to characterize the white blood cell differential of tobacco smoking-induced leukocytosis and describe the longitudinal impact of smoking cessation on this peripheral blood abnormality.
METHODS: Medical records of patients undergoing evaluation by hematologists for persistent leukocytosis were reviewed. Patients in whom leukocytosis was determined to be secondary to tobacco use after exclusion of other causes were identified. Demographic and laboratory data were collected at time of diagnosis. Patients were longitudinally followed and information regarding smoking cessation and follow-up white blood cell values were recorded.
RESULTS: Forty patients were determined to have smoking-induced leukocytosis. The median age was 49.5 years (range: 28-75 years), 24 patients were female, and the mean body mass index (BMI) was 31.5 kg/m2. The mean white blood cell count was 13.3 × 109/L (range: 9.8-20.9 × 109/L); 39 patients had absolute neutrophilia (98%), 21 had lymphocytosis (53%), 20 had monocytosis (50%), and 19 had basophilia (48%). During follow-up, 11 patients either quit (n = 9) or reduced (n = 2) tobacco use. Reduction in tobacco smoking led to a significant decrease in mean white blood cell count (13.2 × 109/L vs 11.1 × 109/L, P = 0.02). The median time to decrease in white blood cell count following reduction in tobacco use was 8 weeks (range: 2-49 weeks).
CONCLUSIONS: Tobacco-induced leukocytosis was characterized by a mild elevation in total white blood cell count and was most commonly associated with neutrophilia, lymphocytosis, monocytosis, and basophilia. Cessation of smoking led to improvement in leukocytosis. Tobacco history should be elicited from all patients presenting with leukocytosis to limit unnecessary diagnostic testing, and counseling regarding smoking cessation should be offered.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:134 |
|---|---|
| Enthalten in: |
The American journal of medicine - 134(2021), 1 vom: 01. Jan., Seite e31-e35 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Smith, Caleb J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 25.01.2021 Date Revised 07.03.2021 published: Print-Electronic CommentIn: Am J Med. 2021 Mar;134(3):e228. - PMID 33637186 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjmed.2020.06.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312591888 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312591888 | ||
| 003 | DE-627 | ||
| 005 | 20231225144736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjmed.2020.06.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312591888 | ||
| 035 | |a (NLM)32682870 | ||
| 035 | |a (PII)S0002-9343(20)30596-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Smith, Caleb J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leukocytosis and Tobacco Use |b An Observational Study of Asymptomatic Leukocytosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2021 | ||
| 500 | |a Date Revised 07.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Med. 2021 Mar;134(3):e228. - PMID 33637186 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a PURPOSE: This study aimed to characterize the white blood cell differential of tobacco smoking-induced leukocytosis and describe the longitudinal impact of smoking cessation on this peripheral blood abnormality | ||
| 520 | |a METHODS: Medical records of patients undergoing evaluation by hematologists for persistent leukocytosis were reviewed. Patients in whom leukocytosis was determined to be secondary to tobacco use after exclusion of other causes were identified. Demographic and laboratory data were collected at time of diagnosis. Patients were longitudinally followed and information regarding smoking cessation and follow-up white blood cell values were recorded | ||
| 520 | |a RESULTS: Forty patients were determined to have smoking-induced leukocytosis. The median age was 49.5 years (range: 28-75 years), 24 patients were female, and the mean body mass index (BMI) was 31.5 kg/m2. The mean white blood cell count was 13.3 × 109/L (range: 9.8-20.9 × 109/L); 39 patients had absolute neutrophilia (98%), 21 had lymphocytosis (53%), 20 had monocytosis (50%), and 19 had basophilia (48%). During follow-up, 11 patients either quit (n = 9) or reduced (n = 2) tobacco use. Reduction in tobacco smoking led to a significant decrease in mean white blood cell count (13.2 × 109/L vs 11.1 × 109/L, P = 0.02). The median time to decrease in white blood cell count following reduction in tobacco use was 8 weeks (range: 2-49 weeks) | ||
| 520 | |a CONCLUSIONS: Tobacco-induced leukocytosis was characterized by a mild elevation in total white blood cell count and was most commonly associated with neutrophilia, lymphocytosis, monocytosis, and basophilia. Cessation of smoking led to improvement in leukocytosis. Tobacco history should be elicited from all patients presenting with leukocytosis to limit unnecessary diagnostic testing, and counseling regarding smoking cessation should be offered | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Leukocytosis | |
| 650 | 4 | |a Neutrophilia | |
| 650 | 4 | |a Tobacco use | |
| 700 | 1 | |a Kluck, Lindsey Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Ruan, Gordon J |e verfasserin |4 aut | |
| 700 | 1 | |a Ashrani, Aneel A |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Ariela L |e verfasserin |4 aut | |
| 700 | 1 | |a Pruthi, Rajiv K |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Mithun Vinod |e verfasserin |4 aut | |
| 700 | 1 | |a Wolanskyj-Spinner, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gangat, Naseema |e verfasserin |4 aut | |
| 700 | 1 | |a Litzow, Mark R |e verfasserin |4 aut | |
| 700 | 1 | |a Hogan, William J |e verfasserin |4 aut | |
| 700 | 1 | |a Sridharan, Meera |e verfasserin |4 aut | |
| 700 | 1 | |a Go, Ronald S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of medicine |d 1946 |g 134(2021), 1 vom: 01. Jan., Seite e31-e35 |w (DE-627)NLM000114472 |x 1555-7162 |7 nnns |
| 773 | 1 | 8 | |g volume:134 |g year:2021 |g number:1 |g day:01 |g month:01 |g pages:e31-e35 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjmed.2020.06.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 134 |j 2021 |e 1 |b 01 |c 01 |h e31-e35 | ||